Close  

FDA flags unregistered drug allegedly effective vs COVID-19

/ 02:33 PM March 30, 2020

MANILA, Philippines — The Food and Drug Administration (FDA) has warned the public against an unregistered drug product called “Prodex-B”, which allegedly has promising effects against the coronavirus disease 2019 (COVID-19).

In an advisory Monday, the FDA said Prodex-B, a combination of Procaine and Dexamethasone with Vitamin B, has “no guaranteed quality, safety and efficacy data which may lead to patient harm.”

ADVERTISEMENT

“Procaine is an anesthetic used to reduce pain on injections, while Dexamethasone is a corticosteroid which must be used cautiously due to its side effects including immunosuppression or weaker immune system leading to vulnerability to infections,” the FDA said.

Consumers who have received the drug are advised to monitor for any adverse reactions.

FEATURED STORIES

For any observed adverse reaction, the individuals are advised to seek medical attention immediately and report the same to the FDA.

The respiratory disease has so far infected over 720,000 worldwide, nearly 34,000 of whom have died.

In the Philippines, 1,418 have been infected with 71 deaths and 42 recoveries.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: Coronavirus, COVID-19, drug, FDA, Health, medicine, Outbreak, pandemic, Quarantine, WHO
For feedback, complaints, or inquiries, contact us.


© Copyright 1997-2020 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.